Literature DB >> 30747957

Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018.

Daniel M Hartung1, Kirbee Johnston1, Jonah Geddes1, Gillian Leichtling2, Kelsey C Priest3, P Todd Korthuis4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30747957      PMCID： PMC6439585          DOI： 10.1001/jama.2018.20391

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  1 in total

1.  Use of Opioid Agonist Therapy for Medicare Patients in 2013.

Authors:  Anna Lembke; Jonathan H Chen
Journal:  JAMA Psychiatry       Date:  2016-09-01       Impact factor: 21.596
  1 in total
  8 in total

1.  Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.

Authors:  Susan L Calcaterra; Richard Bottner; Marlene Martin; Honora Englander; Zoe M Weinstein; Melissa B Weimer; Eugene Lambert; Matthew V Ronan; Sergio Huerta; Tauheed Zaman; Monish Ullal; Alyssa F Peterkin; Kristine Torres-Lockhart; Megan Buresh; Meghan T O'Brien; Hannah Snyder; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

2.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

3.  Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.

Authors:  Shailina Keshwani; Michael Maguire; Amie Goodin; Wei-Hsuan Lo-Ciganic; Debbie L Wilson; Juan M Hincapie-Castillo
Journal:  JAMA Health Forum       Date:  2022-06-24

4.  Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.

Authors:  Kelly E Anderson; Brendan Saloner; Julia Eckstein; Christine E Chaisson; Sarah H Scholle; Lauren Niles; Sydney Dy; G Caleb Alexander
Journal:  Med Care       Date:  2021-05-01       Impact factor: 3.178

5.  Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others.

Authors:  Mark Olfson; Victoria Zhang; Michael Schoenbaum; Marissa King
Journal:  Health Aff (Millwood)       Date:  2020-06       Impact factor: 9.048

Review 6.  How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.

Authors:  Marcus A Bachhuber
Journal:  Addict Sci Clin Pract       Date:  2020-06-29

7.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01

8.  Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.

Authors:  Marc R Larochelle; Sarah E Wakeman; Omid Ameli; Christine E Chaisson; Jeffrey T McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  Med Care       Date:  2020-10       Impact factor: 3.178
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.